Shasun Pharmaceuticals has moved higher by over 5% to Rs 68.90 in otherwise subdued market after the company said it has entered into a licensing agreement with a Swiss-based Debiopharm Group for the manufacturing and commercialization of Huperzine-A.
According to the terms of the agreement, Shasun Pharmaceuticals will be able to use the Debiopharm technology for the manufacture of synthetic Huperzine-A under GMP quality conditions and commercialize it in pharmaceutical and nutraceutical markets, Shasun Pharma said in a press release.
Huperzine-A is a potent and reversible acetyl cholinesterase inhibitor and clinical studies have shown a significant improvement in memory deficit and cognitive performance patents with Alzheimer’s disease.
The stock opened at Rs 65.65 and touched high of Rs 69.80 on BSE. A combined 332,625 shares have changed hands on the counter till 1157 hours on BSE and NSE.
According to the terms of the agreement, Shasun Pharmaceuticals will be able to use the Debiopharm technology for the manufacture of synthetic Huperzine-A under GMP quality conditions and commercialize it in pharmaceutical and nutraceutical markets, Shasun Pharma said in a press release.
Huperzine-A is a potent and reversible acetyl cholinesterase inhibitor and clinical studies have shown a significant improvement in memory deficit and cognitive performance patents with Alzheimer’s disease.
The stock opened at Rs 65.65 and touched high of Rs 69.80 on BSE. A combined 332,625 shares have changed hands on the counter till 1157 hours on BSE and NSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%